Bitcoin reached a new all-time high of $118,900 on Friday, surpassing its previous record of $113,822 set on Thursday. As Read more
Selling software to companies can be a daunting task, especially when it comes to meeting security requirements. Chas Ballew, founder Read more
The world’s richest man buys out one of the most popular social media platforms and uses it as a propaganda Read more
Waymo recently started two “road trips” to Philadelphia and New York City, showing interest in expanding into Northeastern cities. These Read more
Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine. This innovative approach could revolutionize the way we treat our beloved pets.
Gallant’s Target and Progress
Gallant’s initial focus is on a painful mouth condition in cats known as feline chronic gingivostomatitis (FCGS). If successful, this therapy could receive FDA approval as early as 2026. While still an experimental field, studies have shown promising results in dogs with arthritis, improving pain and mobility for up to two years. However, outcomes for kidney disease in cats, another condition Gallant aims to address, have been more varied.
Gallant’s Unique Approach
What sets Gallant apart is its allogeneic therapy using uterine-derived mesenchymal stem cells from a single donor animal of the same species. This method allows for the production of up to 30 million doses, making it more scalable than previous alternatives. Investors, recognizing the potential, have shown significant interest in Gallant’s work.
Company Background and Leadership
Gallant’s founder, Aaron Hirschhorn, previously sold DogVacay to Rover and passed away in 2021. The company is now led by Linda Black, who has been with Gallant since its early days. Overall, Gallant has raised at least $44 million from investors.
Please note a correction: While Gallant’s therapy focuses solely on allogeneic therapy, the article previously indicated otherwise. Xenogeneic therapies involving different species are also being studied, but Gallant is committed to allogeneic therapy exclusively.
